Pharmacokinetics of single- and multiple-dose roflumilast: an open-label, three-way crossover study in healthy Chinese volunteers

Overview of attention for article published in Drug Design, Development and Therapy, November 2018

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (52nd percentile)
Above-average Attention Score compared to outputs of the same age and source (55th percentile)

Mentioned by

patent: 6 patents

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 28 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 6 patents that reference this research output.

Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

Grant US-12042487-B2

United States of America

Roflumilast formulations with an improved pharmacokinetic profile

Grant US-12016848-B2

United States of America

Roflumilast formulations with an improved pharmacokinetic profile

Grant US-12011437-B1

United States of America

Topical roflumilast formulation having improved delivery and plasma half-life

Grant US-12005052-B2

United States of America

Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

Grant US-11992480-B2

United States of America

Topical roflumilast formulation having improved delivery and plasma half-life

Grant US-11819496-B2

United States of America